Latest Conference Articles

Among patients with metastatic gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab, the agent showed promising antitumor activity and a manageable toxicity profile.

Chiara Cremolini, MD, discusses findings from the phase III TRIBE trial that combined FOLFOXIRI with bevacizumab as a frontline treatment for patients with metastatic colorectal cancer.

Eric Van Cutsem, MD, PhD of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the use of trastuzumab for the treatment of advanced HER2-positive gastric cancer.

Intensifying the chemotherapy component of a standard first-line bevacizumab-containing regimen reduced the risk of death by about 20% and doubled the 5-year overall survival (OS) rate among patients with metastatic colorectal cancer (mCRC).

A 'watch and wait' surveillance approach may allow certain patients with rectal cancer to achieve excellent outcomes without immediate surgery.

Patients with newly diagnosed metastatic colorectal cancer (mCRC) who had higher levels of vitamin D in their blood lived a median of 8 months longer and experienced greater disease-free survival after their cancer treatment.

Second-line treatment with the VEGFR2 inhibitor ramucirumab (Cyramza) combined with standard FOLFIRI extended survival by 1.6 months versus FOLFIRI alone in patients with metastatic colorectal cancer (mCRC), according to results from the phase III RAISE trial.

William J. Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses the BOLERO-1 Trial.

As few as five pounds of weight loss can make a significant difference for patients with triple-negative breast cancer, says Rowan Chlebowski, MD, PhD, a medical oncologist at the Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center.

Ann LaCasce, MD, a lymphoma specialist at Dana-Farber Cancer Institute in Boston, discusses the use of brentuximab vedotin and bendamustine in combination for the treatment of patients with relapsed or refractory Hodgkin lymphoma.

Jae H. Park, MD, attending physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses a trial presented at the 2014 ASH Annual Meeting that explored CD19-targeted T cells as treatment for patients with relapsed, refractory B- cell ALL.

Duvelisib (IPI-145), an inhibitor of PI3K-δ and PI3K-γ signaling, had a favorable risk:benefit profile in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) in a phase I study, reported Ian Flinn, MD, PhD

Treatment with the TKI sorafenib in combination with standard chemotherapy increased event-free survival by 11.3 months compared with standard chemotherapy plus placebo in patients with newly diagnosed acute myeloid leukemia.

A 12-gene test for breast cancer recurrence after ductal carcinoma in situ (DCIS) distinguished high- and intermediate- risk patients from those with a low risk

Findings from a long-term analysis of the Women's Intervention Nutrition Study (WINS) show that the deaths of women with hormone receptor–negative breast cancers were reduced by up to 54% when they followed a program to reduce their dietary fat intake, which could provide benefit for patients with triple-negative breast cancer.

Frontline treatment with everolimus (Afinitor) combined with trastuzumab (Herceptin) and paclitaxel failed to delay disease progression versus trastuzumab and paclitaxel alone in patients with HER2-positive advanced breast cancer

Fulvestrant (Faslodex) improved overall survival (OS) by 5.7 months compared with anastrozole as a frontline treatment for postmenopausal women with HR-positive metastatic breast cancer

Rita Nanda, MD, assistant professor of medicine and associate director of the Breast Medical Oncology Program at the University of Chicago, discusses the potential of pembrolizumab (Keytruda) for the treatment of triple-negative breast cancer (TNBC). A recent small-scale trial showed treatment response for 18.5% of patients with PD-L1 positive TNBC.

Older patients with moderate- or high-risk breast cancer had a similar disease-free survival with the bisphosphonate therapy ibandronate alone or in combination with capecitabine.

Five years of tamoxifen continues to offer protection against breast cancer, reducing the risk of breast cancer by 29% in otherwise healthy women at high risk of the disease who have been followed now for 16 to 22 years.

Women with HR+ breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or-to a lesser extent-tamoxifen, compared with standard tamoxifen alone, according to results from the phase III SOFT trial.

The addition of bevacizumab (Avastin) to standard neoadjuvant chemotherapy significantly improved pathologic complete response (pCR) rates in women with basal-like breast cancer compared with non-basal-like subtypes.

Nab-paclitaxel (Abraxane) proved markedly more effective than conventional paclitaxel as part of a neoadjuvant regimen for patients with high-risk early breast cancer in a large German study presented at the 2014 San Antonio Breast Cancer Symposium.

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the potential for immune checkpoint blockage as treatment for patients with advanced breast cancer.

The PD-1 inhibitor pembrolizumab has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer.

The addition of the investigational PI3K inhibitor pictilisib to fulvestrant in patients with metastatic breast cancer yielded some intriguing findings in the phase II FERGI study.